Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-08-13
1999-09-14
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514322, 546198, 546199, A61K 31445, C07D41314
Patent
active
059523514
DESCRIPTION:
BRIEF SUMMARY
This invention relates to certain novel compounds, their synthesis, and their use as a selective alpha 1a adrenoceptor antagonists. More particularly, the compounds of the present invention are useful for treating benign prostatic hyperplasia.
BACKGROUND OF THE INVENTION
Human adrenergic receptors are integral membrane proteins which have been classified into two broad classes, the alpha and the beta adrenergic receptors. Both types mediate the action of the peripheral sympathetic nervous system upon binding of catecholamines, norepinephrine and epinephrine.
Norepinephrine is produced by adrenergic nerve endings, while epinephrine is produced by the adrenal medulla. The binding affinity of adrenergic receptors for these compounds forms one basis of the classification: alpha receptors bind norepinephrine more strongly than epinephrine and much more strongly than the synthetic compound isoproterenol. The binding affinity of these hormones is reversed for the beta receptors. In many tissues, the functional responses, such as smooth muscle contraction, induced by alpha receptor activation are opposed to responses induced by beta receptor binding.
Subsequently, the functional distinction between alpha and beta receptors was further highlighted and refined by the pharmacological characterization of these receptors from various animal and tissue sources. As a result, alpha and beta adrenergic receptors were further subdivided into .alpha..sub.1, .alpha..sub.2, .beta..sub.1, and .beta..sub.2 subtypes. Functional differences between .alpha..sub.1 and .alpha..sub.2 receptors have been recognized, and compounds which exhibit selective binding between these two subtypes have been developed. Thus, in WO 92/0073, the selective ability of the R(+) enantiomer of terazosin to selectively bind to adrenergic receptors of the alpha 1 subtype was reported. The .alpha..sub.1 /.alpha..sub.2 selectivity of this compound was disclosed as being significant because agonist stimulation of the .alpha..sub.2 receptors was said to inhibit secretion of epinephrine and norepinephrine, while antagonism of the .alpha..sub.2 receptor was said to increase secretion of these hormones. Thus, the use of non-selective alpha-adrenergic blockers, such as phenoxybenzamine and phentolamine, is limited by their .alpha..sub.2 adrenergic receptor mediated induction of increased plasma catecholamine concentration and the attendant physiological sequelae (increased heart rate and smooth muscle contraction).
For a general background on the .alpha.-adrenergic receptors, the reader's attention is directed to Robert R. Ruffolo, Jr., .alpha.-Adrenoreceptors: Molecular Biology, Biochemistry and Pharmacology, (Progress in Basic and Clinical Pharmacology series, Karger, 1991), wherein the basis of .alpha..sub.1 /.alpha..sub.2 subclassification, the molecular biology, signal transduction (G-protein interaction and location of the significant site for this and ligand binding activity away from the 3'-terminus of alpha adrenergic receptors), agonist structure-activity relationships, receptor functions, and therapeutic applications for compounds exhibiting .alpha.-adrenergic receptor affinity was explored.
The cloning, sequencing and expression of alpha receptor subtypes from animal tissues has led to the subclassification of the .alpha..sub.1 receptors into .alpha..sub.1a, (Lomasney, et al., J. Biol. Chem., 266:6365-6369 (1991), rat .alpha..sub.1a ; Bruno et al., BBRC, 179:1485-1490 (1991), human .alpha..sub.1a), .alpha..sub.1b (Cotecchia, et al., PNAS, 85;7159-7163 (1988), hamster .alpha..sub.1b ; Libert, et al., Science, (1989), dog .alpha..sub.1b ; Ramarao, et al., J. Biol. Chem., 267:21936-21945 (1992), human .alpha..sub.1b), and most recently, in a study using bovine brain, a new .alpha..sub.1c subtype was proposed (Schwinn, et al., J. Biol. Chem., 265:8183-8189 (1990); Hirasawa et al., BBRC 195:902-909 (1993), described the cloning, functional expression and tissue distribution of a human .alpha..sub.1c adrenergic receptor; Hoehe et al., Human Mol. Genetics
REFERENCES:
patent: 4066722 (1978-01-01), Vandenberk et al.
patent: 4110449 (1978-08-01), Wade et al.
patent: 4470989 (1984-09-01), Henning et al.
patent: 5141930 (1992-08-01), Nakao et al.
patent: 5143923 (1992-09-01), Hrib et al.
patent: 5403847 (1995-04-01), Gluchowski et al.
patent: 5462942 (1995-10-01), Hartog et al.
Chapple "Medical treatment for benign prostatic hyperplasia: surgery still gives the best results" Br. Med. J. v.304, 01198, 1992.
Evans Ben E.
Hoffman Jacob M.
Ponticello Gerald S.
Chang Ceila
Merck & Co. , Inc.
Walton Kenneth R.
Winokur Melvin
LandOfFree
Alpha 1a adrenergic receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha 1a adrenergic receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha 1a adrenergic receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510101